Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2019

At a glance

  • Drugs WT1 protein-specific T-cell therapy Atara/MSKCC (Primary) ; Busulfan; Fludarabine; Melphalan
  • Indications Multiple myeloma; Plasma cell leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jul 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
    • 01 Jul 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top